Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation

Hepatocellular Carcinoma Clinical Trial

— CELPerCutCHC  

Official title:

Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04813861
• Other study ID #: 2020-PI199-99
• Status: Completed
• Start date: January 4, 2010
• Est. completion date: March 2021

Study information

• Verified date: March 2021
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered. If a curative treatment cannot be considered in case of an HCC classified in an intermediate stage, a Transcatheter Arterial Chemoembolization (TACE) can be proposed. In case of a partial response or the treatment of some lesions of a multifocal HCC, a combined treatment by stereotaxic radiotherapy (CK), radiofrequency ablation (RFA) or microwave ablation (MWA) may be initiated in accordance with a decision of the multidisciplinary consultation meeting.

The aim of this study was to evaluate the clinical outcome of HCC receiving MWA, RFA or CK after downstaging with TACE.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: March 2021
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• a HCC treated by TACE followed by RFA, MWA and/or CK

• from 01/2010 to 12/2020

• treated by Nancy Regional University Hospital (TACE, RFA, MWA) and Institut de Cancérologie de Lorraine (CK)

Exclusion Criteria:

• Combined treatment over one year following the last TACE

• No baseline, in between or after combined treatment imaging

• Lesion appeared after TACE treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Locations

Country	Name	City	State
France	CHRU de Nancy	Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lesion Response	Lesion response after combined treatment	4-6 weeks after BWA or RFA or 3-6 months after CK
Secondary	Delayed Lesion Response	Lesion response a year after combined treatment	1 year after BWA, RFA or CK